Average Co-Inventor Count = 8.90
ph-index = 19
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (76 from 124 patents)
2. Valo Health, Inc. (14 from 29 patents)
3. Valo Early Discovery, Inc. (12 from 15 patents)
4. Novo Nordisk Healthcare Ag (6 from 88 patents)
5. Forma Tm2, Inc. (4 from 4 patents)
6. H. Lee Moffitt Cancer Center and Research Institute, Inc. (1 from 286 patents)
112 patents:
1. 12304904 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
2. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
3. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
4. 12128035 - Activating pyruvate kinase R
5. 12122778 - Activating pyruvate kinase R
6. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
7. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound
8. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
9. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound
10. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
11. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
12. 11844787 - Activating pyruvate kinase R
13. 11739071 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
14. 11702412 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
15. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators